Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer

01-Mar-2019 - Germany

Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough. As a result of the trial initiation, Evotec received a payment of € 3 m.

In October 2012, Evotec and Bayer began their multi-target discovery alliance with the shared goal to discover three clinical candidates with a focus in the field of endometriosis. The successful and productive long-term alliance ended in 2018, generating six first-in-class pre-clinical candidates three of which have progressed into Phase I clinical trials. Bayer advanced a first programme into a Phase II trial in chronic cough in July 2018 and has now initiated a further candidate into a second Phase II trial for the same indication.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “Our long-term alliance with Bayer represents our continued commitment to bring new therapeutics options to millions of patients. We are pleased to see a second compound from this alliance moving into Phase II studies for chronic cough, a debilitating condition affecting about ten percent of the global population and with no approved, curative therapy.”

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?